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Several lines of evidence suggest that platelet-derived growth factor A chain (PDGF-A) is required for normal embryonic
cardiovascular development. To test this directly, we introduced anti-PDGF-A neutralizing antibodies into mouse deciduas
in utero at Embryonic Days (E) 8.5, 9.5, and 10.5. This resulted in the selective disruption of PDGF-A ligand±receptor
interactions in vivo for a period of 18±24 hr and allowed us to assess both if PDGF-A is required for cardiovascular
development and when it is required. Embryos collected 48 hr after antibody treatment displayed severe cardiovascular
abnormalities. These included both atrial and ventricular myocardial hypertrophy, epicardial and endocardial abnormalities,
and aortic dilation, among others. Although heart abnormalities were observed in embryos treated at all three ages, they
were more common in embryos treated at E8.5. In contrast, only embryos treated at E10.5 exhibited signi®cant aortic
dilation. This work (1) demonstrates directly for the ®rst time that PDGF-A is required for normal cardiovascular develop-
ment, (2) identi®es several processes that require PDGF-A, and (3) de®nes discreet developmental periods during which
these PDGF-A-dependent processes require the factor. q 1996 Academic Press, Inc.
INTRODUCTION necessary for signal transduction in vivo, although a low-
af®nity interaction of PDGF-bb receptors with high concen-
trations of PDGF-AB may also result in PDGF signalingThe platelet-derived growth factors (PDGF) are a group of
(Seifert et al., 1989, 1993).three ligands composed of homo- and heterodimers of the
Homozygous deletion of either the PDGF-B chain (LeveenPDGF-A chain (PDGF-A) and PDGF-B chain (PDGF-B) (Ross
et al., 1994) or bPDGFR (Soriano, 1994) gene results in pre-et al., 1986). Both PDGF-A and B transcripts are detected
natal or perinatal death. Similarly, mice homozygous forin a variety of tissues during development (Sasahara et al.,
the naturally occurring Patch mutation, which includes a1991; Yeh et al., 1991; Orr-Urtreger and Lonai, 1992). There
deletion of the aPDGFR gene, die prenatally (Grunebergare two known PDGF receptors, aPDGF receptor (aPDGFR)
and Truslove, 1960; Stephenson et al., 1991). One-quarterandbPDGF receptor (bPDGFR), both of which are expressed
of homozygous PDGF-B knockout mice die before birth,throughout most of postimplantation mouse development
while the remaining three-quarters die immediately after(Rappolee et al., 1988; Mercola et al., 1990; Morrison-Gra-
birth. Both embryos and newborns are hemorrhagic andham et al., 1992; Orr-Urtreger et al., 1992; Schatteman et
edematous (Leveen et al., 1994). Embryonic Day 17.5 (E17.5)al., 1992). These receptors dimerize to form both homo- and
and older embryos and newborns have enlarged and de-heterodimers which have different ligand binding pheno-
formed hearts and dilated thoracic arteries (Leveen et al.,types (Seifert et al., 1989). PDGF-induced receptor dimeriza-
1994). Homozygous Patch (Ph) mutant mice exhibit evention appears to be required for signal transduction (Heldin
more severe cardiovascular abnormalities which include in-et al., 1989). Because PDGF-A chain interacts with bPDGFR
complete aorticopulmonary and heart septation, valve ab-only weakly, only six ligand receptor combinations result
normalities, thinned and distorted myocardium, a reducedin high-af®nity binding. High-af®nity binding appears to be
number of vascular smooth muscle cells, and aberrant pat-
terning of large vessels (Morrison-Graham et al., 1992;
Schatteman et al., 1995). Interestingly, while deletion of1 To whom correspondence should be addressed at Center for
the bPDGFR gene results in hematological and other devel-Molecular Medicine, Institute of Biotechnology, University of
opmental abnormalities, the lack of bPDGFR does not re-Texas Health Science Center, 15355 Lambda Drive, San Antonio,
TX 78245-3207. Fax: (210) 567-7277. sult in severe cardiovascular abnormalities (Soriano, 1994).
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(0.2±0.3 mm diameter) was passed through the uterus and insertedThese ®ndings collectively suggest that PDGF-A acting
into the decidua. E8.5, E9.5, and E10.5 embryos were injected withthrough aPDGFR is the primary PDGF pathway required
0.4±0.5, 0.6±0.7, or 0.7±0.8 ml, respectively, of IgG in 0.9% salinefor normal embryonic cardiovascular development.
or with 0.9% saline alone as a vehicle control. After injection thePDGF and PDGFR knockout mice demonstrate directly
uterus was replaced and the mother was surgically closed with 5-the requirement for the PDGF system in morphogenesis.
0 silk and allowed to recover. Mothers were reanesthetized and
However, they are of limited use in delineating the morpho- killed by cervical dislocation at various times after injection and
genic mechanism through which the PDGF system exerts the embryos were removed. Embryos were either snap frozen in
its embryonic effects. For example, although PDGF-A and liquid nitrogen and stored at 0707C or ®xed in methyl Carnoy's
aPDGFR are expressed in the mouse central nervous system ®xative (60% methanol, 30% chloroform, 10% acetic acid) for 36
hr or more.after E13 (Yeh et al., 1991; Schatteman et al., 1992; Yeh et
al., 1993) few Ph/Ph mice survive past E14 (Gruneberg and
Truslove, 1960). The few embryos that do survive past E14
Concentration of Injected IgG in the Embryoexhibit central nervous system defects, but it is impossible
to ascertain whether these abnormalities are due to the lack To determine the time it takes for injected IgG to reach the
of aPDGFR in the nervous system or are secondary to poor embryo after decidual injection, and to determine how long the
embryonic health. Thus, it is dif®cult to assess the role of IgG remains in the embryo, 10 mg/ml rabbit or goat IgG stock
aPDGFR in central nervous system development. Even for solutions (Sigma, St. Louis, MO) in 0.9% saline or 0.9% saline alone
structures that do form during the period of embryonic sur- were injected into the decidua of E8.5, E9.5, and E10.5 embryos. At
1, 3, 6, 12, 18, and 24 hr after injection embryos from two to fourvival, information from mutants is limited. Because, for
litters at each age were collected and snap frozen in liquid nitrogen.example, the Patch deletion critically affects the neural
Lysates were prepared by dounce homogenization of frozen em-crest early in development, it is impossible to determine if
bryos (with extraembryonic tissues removed) in a minimum vol-the deletion also affects these cells at later stages of develop-
ume of ice-cold lysis buffer (50 mM Tris, pH 7.5, 1 mM EDTA,ment (Gruneberg and Truslove, 1960; Morrison-Graham et
1% Triton, 0.9% NaCl, and 1 mM PMSF). The crude lysates were
al., 1992). In addition, the ventricular wall of both PDGF- centrifuged (13g for 5 min) and the supernatants collected. For ly-
B knockouts and Ph/Ph embryos is thin. Is this thinning a sates from embryos injected at E8.5, all but 2 embryos in the litter
result of the requirement for PDGF-B or aPDGFR at one were pooled. At E9.5 lysates were made from pools of 3±4 embryos,
critical development stage or the cumulative effect of the and at E10.5 lysates were made from 1±2 embryos.
lack of PDGF signaling over an extended developmental A sandwich ELISA was used to determine the concentration of
IgG in the clari®ed embryo lysate (Harlow and Lane, 1988). Microti-period (Schatteman et al., 1992, 1995)?
ter plate wells were coated overnight (O/N) at 47C with 50 ml 20 mg/To circumvent these limitations and to complement
ml swine anti-rabbit or rabbit anti-goat IgG (DAKO) in Dulbecco'sanalyses of knockout mice, we adapted the method of John-
phosphate-buffered saline (PBS), blocked with 150 ml 3% bovineson et al. (1989) and Carroll et al. (1992) to determine the
serum albumin (BSA) and 0.02% sodium azide in PBS for 2 hrprecise temporal requirements of the developing cardiovas-
at room temperature (RT), and incubated O/N at 47C with 50 ml
cular system for PDGF-A. Antibodies that block the func- embryonic extracts. Plates were washed with 500 ml PBS per well
tion of PDGF-A were injected into the decidua of mouse 41 5 min, incubated with 0.1 mg/ml biotinylated horse anti-goat
embryos in utero at various times during development. IgG (or goat anti-rabbit) (Vector) for 2 hr, washed again, and incu-
Analysis of the embryos collected 48 hr after injection re- bated with 0.3 mg/ml alkaline phosphatase-conjugated streptavidin
vealed that PDGF-A is required for normal embryonic car- (Zymed) for 2 hr. Plates were washed 31 5 min with PBS, then
rinsed twice with 0.5 mM MgCl2 in 10 mM diethanolamine, anddiovascular development. Further, the speci®c abnormali-
reacted with 50 ml 0.5 mg/ml disodium p-nitrophenyl phosphateties observed were associated with discreet embryonic peri-
in the rinse buffer. The absorbance at 405lwas read and the concen-ods of antibody administration.
tration of IgG determined by comparison to absorbance of IgG stan-
dards.
Protein content of the clari®ed extracts was determined by a
MATERIALS AND METHODS modi®ed Lowry assay (1951) using Bio-Rad (Hercules, CA) protein
reagent according to manufacturer's instructions and compared to
bovine serum albumin standards. IgG concentrations were ex-Mating of Mice and in Utero Injection
pressed as ng/mg of total soluble protein.
Males were mated with two females for 10 hr in the dark, and
females were examined for the presence of a vaginal plug (indicating
pregnancy) at the end of this period. Mid dark cycle was designated Distribution of Injected IgG in the Embryo
E0. To reduce variability among embryos, matings were done in
the inbred strain C57Bl/6J. This is also the background in which Two embryos from each of the litters examined for IgG concen-
Patch mice are normally maintained, and the strain has been found tration by ELISA were set aside and ®xed in methyl Carnoy's. These
to be particularly susceptible to the mutation (Schatteman et al., embryos were dehydrated, paraf®n embedded, sectioned at 8 mm,
1992). and examined by immunocytochemistry (ICC) to determine the
Pregnant mothers were anesthetized with sodium pentobarbital distribution of injected IgG. After deparaf®nization, sections were
(90 mg/gm), swabbed with alcohol, and a 12-in longitudinal abdomi- incubated 30 min in 0.6% H2O2 in PBS, washed 21 10 min in PBS,
then incubated 1 hr in PBS with 1% BSA. Slides were then incu-nal incision was made to expose the uterus. A glass injection pipette
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bated 1 hr at room temperature in 0.5 mg/ml biotinylated goat anti-
rabbit IgG or horse anti-goat IgG (Vector), washed 31 20 min in
PBS, incubated 1 hr at room temperature with 1 mg/ml horseradish
peroxidase-conjugated streptavidin (Vector), and washed 31 20 min
in PBS. Slides were reacted 5±20 min with 760 ng/ml 3,3*-diamino-
benzidine (DAB) in 0.3% H2O2 in 0.1 M Tris, pH 7.6.
Characterization of Anti-PDGF-A
Neutralizing Antibody
An anti-PDGF-A rabbit polyclonal neutralizing antibody was
generated by immunizing rabbits with puri®ed human recombi-
FIG. 1. Concentration of injected IgG in embryos. The concentra-nant PDGF-AA homodimer that had been produced in yeast Sac-
tion of injected IgG in the embryo was measured at various timescharomyces cerevisiae (Hart et al., 1990). The antibody containing
after injection by ELISA and expressed as nanograms of injectedserum and preimmune serum were puri®ed by protein A±Sepha-
IgG per milligram of total protein in the embryo extracts. Bars,rose chromatography and then dialyzed against PBS. The anti-
SEM.PDGF-A antibody has less than 1% cross-reaction to PDGF-B chain
as detected by immunoprecipitation of 125I-PDGF-BB and neutral-
ization of PDGF-BB mitogenic activity (Hart et al., 1990).
To verify that the antibody recognizes mouse PDGF-A, whole
E14 mouse embryos lysates were prepared as for the ELISA assays ally, four E8.5 litters injected with anti-PDGF IgG and three E8.5
above. Clari®ed lysates were mixed with an equal volume of 21 litters injected with control IgG were collected 60 hr after injection.
sample buffer containing 7.7 mg/ml dithiothreitol (SB-DTT). As a Finally, one litter of uninjected embryos was also collected for each
control, 500 ml of whole blood from heart puncture of anesthetized time point.
(90mg/gm pentobarbital) adult female mice was drawn into a plastic
syringe containing 50 ml of 100 mM sodium citrate. The blood was
centrifuged (20 min at 250g) in a plastic tube to pellet red blood Analysis of Anti-PDGF-A IgG-Injected
cells. After removing the supernatant, the pellet was washed 21 and Control Embryos
by resuspending the cells in PBS and centrifuging (20 min at 250g).
At the time of removal from the mother, embryos were examinedThe pellet was resuspended in 20 ml of 21 SB-DTT. Both samples
under a dissecting microscope and photographed. Embryos werewere vortexed vigorously 30 sec, boiled 5 min, and then centrifuged
then ®xed in methyl Carnoy's for 36 hr or more, paraf®n embedded,5 min at 8200g. The supernatants were loaded on a 12% SDS±
sectioned at 8 mm, and, after deparaf®nization, stained with hema-PAGE gel as described (Harlow and Lane, 1989).
toxylin and eosin. Developmental ages were determined accordingAfter SDS±PAGE, samples were transferred to nitrocellulose
to Theiler (1989) from photographs and histological analysis. Of(Gibco-BRL, Gaithersburg, MD) for Western analysis as described
embryos injected at E8.5 and collected 48 hr later, 34 anti-PDGF-A(Harlow and Lane, 1989). Brie¯y, after blocking for 2 hr in TTBS
IgG-treated, 14 control-injected, and 5 uninjected control embryos(0.1 M Tris, 0.9% NaCl, 0.1% Tween 20) containing 5% nonfat dry
were examined histologically. Of embryos injected at E9.5, 18 anti-milk, membranes were incubated for 3 hr in TTBS with 2% nonfat
PDGF-A IgG-injected, 12 control-injected, and 3 uninjected controldry milk (Blotto) containing anti-PDGF-A IgG at 5.3 mg/ml. Mem-
embryos were examined. Of embryos injected at E10.5, 32 anti-branes were then washed 31 10 min in Blotto, incubated 1 hr in
PDGF-A IgG-injected, 29 control-injected, and 6 uninjected control0.5 mg/ml horseradish peroxidase-conjugated goat anti-rabbit IgG
embryos were examined. Not all features were examined in all(Amersham, Arlington Heights, IL) in Blotto, and washed 31 10
embryos due to loss of sections or damage during collection. Formin in TTBS. Blots were developed in chemiluminescence reagent
all statistical analyses, x2 analysis was used, except that a t test(Dupont, Boston, MA) diluted 1:1 with H2O.
was used to compare aortic circumference of E10.5 injected anti-
PDGF-A-treated embryos with that of controls.
In Utero Injection of Embryos with
Anti-PDGF-A IgG
RESULTS
To verify that injection of anti-PDGF IgG results in antibody
being distributed in a manner similar to control IgG, two litters of
Embryonic Distribution and Titer of Injected IgGsix E10.5 embryos were injected with 0.7±0.8 ml of a 5.28 mg/ml
solution of anti-PDGF-A IgG. The embryos were collected 6 hr Decidua were injected in utero at E8.5, E9.5, and E10.5
after injection and analyzed by ICC for the presence of injected IgG with IgG and collected at various times after injection to
as above. establish how long injected IgG takes to reach an embryo,
To determine if PDGF-A is required for normal cardiovascular and what its titer is in the embryo. Treated embryos were
development, embryos were treated with anti-PDGF-A IgG. Seven
homogenized for analysis of IgG content by ELISA. FigureE8.5, 4 E9.5, and 7 E10.5 litters were injected with the appropriate
1 summarizes the ELISA data for E9.5 and E10.5 injectedvolume of a 5.28 mg/ml solution of anti PDGF-A IgG as described
embryos. Data from embryos injected at E8.5 is not includedabove. Three E8.5, 3 E9.5, and 5 E10.5 litters were injected with
because although IgG could be detected in the embryos, thenonimmune rabbit IgG, 5.28 mg/ml stock solution (Sigma) to serve
as controls. Embryos were collected 48 hr after injection. Addition- embryos were too small to allow protein concentrations to
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FIG. 2. Distribution of injected IgG in embryos. Detection of IgG by ICC in 8-mm parasagittal sections. (A) E10.5 embryo injected with
anti-PDGF-A IgG and collected 6 hr later. Anti-PDGF-A IgG immunoreactivity is detected throughout the embryo including the mesen-
chyme (M), branchial arches (A), heart (H), and limb (L), which express PDGF receptors, and in the brain (B) and spinal cord (S), which do
not. Ventricle (V). (B) No background staining was observed in E10.5 embryos injected with saline and collected 6 hr later. Bar, 500 mm.
be measured accurately. No difference was seen between ular weights of approximately 45 and 28 kDa (Fig. 3), similar
goat and rabbit IgG-injected embryos so the data were to the molecular weights reported for immature (44 kDa)
pooled. IgG diffuses into the embryo rapidly, but peak titers and mature (30±31 kDa) baboon PDGF-A (Kraiss et al.,
(of about 230 ng/mg) are not achieved until approximately 1993). No bands were detected in platelet-free preparations
6 hr after injection (Fig. 1). By 18 hr, concentrations have of adult red blood cells which do not contain PDGF (Fig. 3)
dropped signi®cantly but IgG is still present and remains or when a nonimmune IgG was used (data not shown).
at approximately 50 ng/mg for at least 6 more hr (Fig. 1).
This lower concentration of IgG does not represent a return
to baseline since no IgG was detected in saline or uninjected
controls. (Saline and uninjected controls were obtained
from different litters than IgG-injected embryos, because
IgG could be detected in uninjected littermates of IgG-in-
jected embryos.)
Embryos injected as above were also examined by immu-
nocytochemistry (ICC) to determine the distribution of in-
jected IgG. IgG was detected in embryos at all ages exam-
ined and was distributed throughout the embryo for at least
18 hr after injection (data not shown). Similar results were
obtained when anti-PDGF-A IgG was used. The antibody
was distributed throughout the embryo, and for at least 6
hr, antibody distribution did not correlate with the distribu-
tion of aPDGFR (Schatteman et al., 1992) (Fig. 2A). The
relative intensity of immunoreactivity was consistent with
IgG titer data, although ICC was less sensitive than the
ELISA. No reactivity was detected in saline-injected or un-
injected controls (Fig. 2B).
Characterization of Anti-PDGF-A IgG
To verify that the anti-PDGF-A IgG which was generated FIG. 3. Western blot analysis of mouse tissue and blood extracts
against human recombinant PDGF-A recognizes mouse with anti-PDGF-A IgG. (A) Molecular weight standards. (B) Extract
PDGF-A, Western analysis was performed. Two bands were of E14 whole mouse embryo. (C) Extract of platelet-free adult
mouse red blood cells.detected in embryo extracts representing proteins of molec-
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Anti PDGF-A Injection Leads to Atrial and
Ventricular Wall Abnormalities
Normal atrial wall organization with clear delineation
between the epicardium, myocardium, and endocardium
was observed in 54 of 55 control IgG-injected and 14 of 14
uninjected embryos (Figs. 5A and 5C). However, in 10 of 34
(29%) E8.5, 3 of 18 (17%) E9.5, and 5 of 32 (16%) E10.5 anti-
PDGF-A IgG-injected embryos, small or large patches of
severe myocardial disorganization were observed. In se-
verely affected embryos of all three ages, the epicardium
was lifted away from the myocardium and the interleaving
space was ®lled with cells and/or extracellular matrix (Fig.
5B). In other areas the epicardium appeared to be absent
(Fig. 5B). The myocardium was thickened, probably by a
FIG. 4. Injection of anti-PDGF-A at E10.5 leads to aortic dilation. combination of hypertrophy, hyperplasia, and excessive ex-
Hematoxylin- and eosin-stained 8-mm transverse sections of E12.5 tracellular matrix production. In some cases cells and extra-
lower thoracic aorta. (A) Cross section through the largest aorta cellular matrix nearly ®lled the atrial cavity (Fig. 5B). In
(Ao) of 11 rabbit IgG-injected embryos. (B) Cross section through most regions of myocardial hypertrophy it was unclear
the largest aorta of anti-PDGF-A IgG-treated embryos. The cross- whether an endocardium was present since cells lining the
sectional area of the aorta in B is three times that of the control
atrial lumen were hypertrophic and resembled neither myo-aorta in A. Bar, 100 mm.
cardial nor endocardial cells (Fig. 5D). In some areas where
the endocardium appeared to be present, as with the epicar-
dium, it was lifted from the myocardium by interleaving
Injection of Anti-PDGF-A Antibody Results in cells and extracellular matrix material (Fig. 5B).
Aortic and Veinous Dilation Most commonly the atria were affected, but in 12 of 84
(14%) (P  .001) embryos the ventricular wall was also ab-To perturb the interaction of PDGF-A with its receptor,
normal. In most of these embryos the ventricular wall ab-anti-PDGF-A IgG was injected in utero into the decidua of
normalities were mild and were manifest as a thickeningmouse embryos at E8.5, E9.5, or E10.5, and the embryos
of the ventricular wall, but in 4 (5%) (P  .04) embryos, thewere collected 48 hr later. The resorption rates of anti-
ventricular abnormalities were more severe, such that thePDGF-A- and nonimmune IgG (control)-injected embryos
ventricular cavity was nearly ®lled with cells and extracel-of 8 and 4% at E8.5 (P  .31), 18 and 17% at E9.5 (P  .85),
lular matrix material (Figs. 6B and 6D). The wall myocar-and 15 and 20% at E10.5 (P  .26), respectively, were not
dium was thickened, but whether this was due to hyperpla-signi®cantly different. Nonresorbed abnormal embryos
sia, hypertrophy, or extracellular matrix abnormalities waswere present in both anti-PDGF-A IgG- and control-injected
unclear. Unlike the atria, the ®lling of the ventricles ap-litters as determined by gross visual observation. However,
peared to be due primarily to hypertrabeculation rather thanonly grossly normal embryos were examined, because the
a simple thickening of the ventricular wall (Figs. 6B andabnormalities observed were similar between the two
6D). The epicardium was typically intact although slightlygroups and were no more frequent in anti-PDGF-A IgG-
lifted from the myocardium (Fig. 6B). Normally at E12.5,injected embryos (4%) than in controls (8%) (P  .42).
some portions of the epicardium covering the ventricles isIn anti-PDGF-A IgG-treated embryos injected at E8.5 and
loosely adherent while in other parts it is tightly adheredE9.5, the lower thoracic aorta appeared to be slightly in-
(or at least closely apposed) to the myocardium. However,¯ated, although neither the abdominal aorta nor veins were
even in regions where the myocardium appeared normal,noticeably dilated. Examination of anti-PDGF-A IgG-
the regions of adherent epicardium were smaller and thetreated embryos injected at E10.5 revealed huge dilation of
extracellular space between the epicardium and myocar-the aorta, as well as dilation of large veins although to a
dium in nonadherent regions was typically wider than inlesser extent. In 11 of 23 anti-PDGF-A IgG-injected em-
controls (data not shown). Ventricles of all injected (55) andbryos, the aortas examined were larger than the largest of
uninjected (14) controls appeared normal (Figs. 6A and 6C).11 control aortas, and 17 anti-PDGF-A IgG-treated aortas
were larger than the third largest control aorta. The largest
anti-PDGF-A IgG-treated aorta (Fig. 4B) had a cross-sec- Subpericardial Blood and Other Abnormalities Are
tional area three times greater than that of the largest con- Observed in Anti-PDGF-A-Treated Embryos
trol (Fig. 4A), and the mean cross-sectional area of anti-
PDGF-A-treated embryos was signi®cantly larger (3.3 1 104 Small amounts of subpericardial blood, possibly the result
of breakage of small blood vessels, were occasionally ob-mm2) than that of controls (2.11 104 mm2) (P .01). In most
of the distended aortas, the vessel wall was thin relative to served in both anti-PDGF-A IgG- and control-injected em-
bryos at all ages, although blood was more common in anti-that of controls (Fig. 4).
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PDGF-A IgG-treated embryos. However, of 21 anti-PDGF-A
IgG-treated embryos injected at E10.5, subpericardial blood
was seen in 3 at the time of dissection, and large amounts
of blood were seen in 5 more by histological analysis (Fig.
7B), but large amounts of blood were not seen in controls
(Fig. 7A) (P  .001). No broken blood vessels were apparent
in these embryos, but we routinely observed tiny holes in
the heart wall in the atrioventricular ring of the heart in
anti-PDGF-A IgG-treated embryos, which were rarely pres-
ent in control embryos. Further, two anti-PDGF-A IgG-
treated embryos injected at E10.5 had large transmural per-
forations of the heart wall in this region (Fig. 8) that could
be seen in many histological sections.
Holes in the anterior thoracic wall were present in anti-
PDGF-A IgG-treated embryos injected at E10.5. Holes were
found in 5 of 23 anti-PDGF-A IgG-injected embryos, and an
additional 5 had a thinned wall relative to controls (data
not shown). In the one embryo with a large hole, the heart
was malpositioned, having rotated toward the right side
(data not shown).
DISCUSSION
aPDGFR, the receptor subunit that mediates biological
activity of PDGF-A, is found in both neural crest and meso-
dermal components of the cardiovascular system during de-
velopment. aPDGFR expressing neural crest derivatives in-
clude the spiral septum of the out¯ow tract, and the tho-
racic aorta, while mesodermal derivatives include the
atrioventricular septal cushions, primitive trabeculae of the
heart, portions of the myocardium and epicardium, and the
mesenchyme from which blood vessels condense (Mor-
rison-Graham et al., 1992; Schatteman et al., 1992, 1995).
No expression is detected in the endocardium at any stage
of development. Table 1 summarizes the abnormalities we
FIG. 5. Anti-PDGF-A injection leads to atrial abnormalities. 8-
mm hematoxylin- and eosin-stained sections of atria from embryos
injected at E10.5 and collected at E12.5 with rabbit IgG (A, C)- and
anti-PDGF-A IgG-injected (B, D) embryos. (A) The epicardium (Ep),
myocardium (M), and endocardium (En) of the atrial wall can be
seen surrounding a large open right atrial cavity (RA). (B) A thick
eosinophilic myocardium can be seen surrounding a small right
atrial cavity. The epicardium is generally intact, but is pulled away
from the myocardium, and in some regions the epicardium may be
absent (open arrowhead). Hypertrophic cells line the atrial cavity,
but it is unclear whether these are endocardial or myocardial cells.
(C) Continuous layers of epicardium and endocardium can be seen
ensheathing the myocardium. (D) Normal looking atrial wall can
be seen adjacent to a region of hypertrophy. In the hypertrophic
region a characteristic band of eosinophilic material splits what
appear to be two layers of myocytes. The myocytes are surrounded
both lumenally and ablumenally by large indistinct cells that do
not resemble either normal epi- or endocardial cells. Bars: A and
B, 50 mm; C and D, 25 mm.
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FIG. 6. Anti-PDGF-A injection leads to ventricular abnormalities. 8-mm hematoxylin- and eosin-stained sections of atria from embryos
injected at E10.5 with rabbit IgG (A, C) or anti-PDGF-A IgG (B, D) and collected at E12.5. (A) Open ventricular cavity with normal
trabeculation and association of epicardium (P) with the myocardium (M). (B) Ventricle with an intact epicardium (P) surrounding the
eosinophilic ventricular wall myocardium (M). The space separating the myocardium and epicardium is larger than that seen in the
ventricle in A. The ventricular cavity is nearly ®lled with cells and extracellular matrix material. (C) High-power view of ventricular wall
and trabeculae surrounded by endocardium (N). (D) High-power view of ventricle. No well-formed trabeculae can be seen, although what
appear to be endocardial cells (N) are present. Eosinophilic extracellular matrix material (E) can also be seen. Bars: A and B, 50 mm; C and
D, 25 mm.
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were less common and less extensive than atrial thickening
and were observed only in embryos exhibiting severe atrial
wall abnormalities. This suggests that the atrial wall is
more sensitive to PDGF-A deprivation. Further, it appears
that the heart wall may be more sensitive to anti-PDGF-A
IgG-induced defects at E8.5 than at E9.5 or E10.5 since atrial
thickening was found in 29% of the younger embryos com-
pared to 16% in the older embryos (P  .04).
Also consistent with the pattern of aPDGFR distribution
is the ®nding of small myocardial perforations in the atrial±
ventricular ring, which expresses high levels of aPDGFR
during development (Schatteman et al., 1995). In this region
the myocardium which surrounds the atrioventricular
cushions is typically thin in all embryos. For this reason,
small holes in the myocardial wall could be created as a by-
product of tissue sectioning. However, although we rou-
tinely observed holes in this region in anti-PDGF-A IgG-
treated embryos, they were rarely present in control em-
bryos and when present they were small. Further, in two
anti-PDGF-A IgG-treated embryos, the perforations were
large and persisted through many sections.
We have previously shown extravascular blood to be com-
mon in Patch embryos, so it was not surprising that subperi-
cardial blood was found in anti-PDGF-A IgG-treated em-
bryos. However, in Patch embryos, embryonic bleeding was
attributed to vascular rupture which was a consistent ®nd-
ing, but in anti-PDGF-A IgG-injected embryos, no major
vessel ruptures were apparent. Thus, while the small
amount of blood observed in embryos treated at E8.5 could
be explained by the undetected rupture of small blood ves-
sels, leakage through the myocardium is a more plausible
explanation for the large amounts of subpericardial blood
FIG. 7. Subpericardial blood is present in anti-PDGF-A-treated observed in embryos injected at E10.5. This is further sup-
embryos. Parasagittal hematoxylin- and eosin-stained 8-mm sec- ported by the fact that extravascular blood was not observed
tions of E12.5 heart and pericardial cavity from rabbit IgG (A)- throughout the embryos, but was con®ned to the pericar-
and anti-PDGF-A IgG-injected (B) embryos. (A) No blood is present dium. Leakage may also be occurring in regions of myocar-
within the subpericardial space (P) surrounding the ventricle (V) and dial hypertrophy where the normal myocardial organization
atrium (A). (B) Large amounts of subpericardial blood are present in
is disrupted. Interestingly, anti-PDGF-A IgG may inducethe pericardial space. Bar, 150 mm.
vascular rupture at later stages of development, since in
preliminary studies hematomas and purpura are present on
most embryos treated with anti-PDGF-A IgG at E12.5
(Schatteman, unpublished). Perhaps the initially slight dila-observed in the cardiovascular system when the PDGF-A/
aPDGFR system was temporarily disrupted during em- tion of the aorta that increases as development progresses
is an early indicator of the dependence of blood vessels onbryogenesis.
The patchiness of atrial and ventricular wall abnormali- PDGF-A for normal development, but that dependence is
not critical until later in development. Indeed, embryos thatties in the anti-PDGF-A IgG-injected embryos is consistent
with the pattern ofaPDGF receptor expression which is also lack PDGF-B do not develop hemorrhages until just prior
to birth (Leveen et al., 1994).patchy in the myocardium and epicardium (Schatteman et
al., 1992, 1995). Whether the abnormalities observed in the The ®nding of an open thoracic cavity or thinned thoracic
wall is consistent with the phenotype of Ph/Ph mice in whichheart wall are due to the effects of PDGF deprivation on
the epicardium or myocardium or both could not be deter- the thoracic wall is consistently open or thin. What was sur-
prising, however, was that although no thinning was apparentmined. However, since the endocardium does not express
detectable aPDGFR at any stage of development (Schatte- in embryos treated at either E8.5 or E9.5, embryos treated at
E10.5 had thinned or open walls. Further, preliminary analysisman et al., 1995), the lack or hypertrophy of endocardium
in regions of myocardial thickening is clearly a nonautono- of embryos injected at E12.5 showed no thoracic wall abnor-
malities (Schatteman, unpublished). Thus, the dependence onmous event and is probably due to aberrant myocardial sig-
naling. Ventricular wall thickening and hypertrabeculation PDGF-A for thoracic wall formation may be speci®c for one
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FIG. 8. Injection of anti-PDGF-A induces myocardial perforations. Hematoxylin- and eosin-stained 8-mm oblique section of E12.5 heart
injected with anti-PDGF-A IgG. A patent transmural channel (arrows) can be seen in the right ventricular (RV) wall in the atrioventricular
ring near the atrioventricular cushions (C). Right atrium (RA). Left ventricle (LV). Bar, 100 mm.
stage of development. Additionally, since the thoracic wall is the upper (neural crest-derived) thoracic aorta. Many of the
observed defects were identical to those seen in Patch mice.closed in early stage embryos, the ®nding that anti-PDGF-A
IgG treatment led to an open wall suggests that PDGF-A may However, in Patch mice, in addition to a broad spectrum of
mesodermally associated abnormalities, embryos are severelybe controlling cell adhesion processes.
All of the abnormalities discussed above are associated with dysmorphic in structures derived from the neural crest. The
lack of a neural crest-associated phenotype may indicate thatmesodermally derived tissues. Notably, even dilation of the
aorta was con®ned to the lower thoracic and abdominal (meso- the mesoderm is more susceptible to disruption of PDGF-A-
mediated signaling than is the neural crest at the time pointsdermally derived) portion of the vessel and was not seen in
tested. Either antibody titers may have been insuf®cient to
affect the neural crest or the disruption of PDGF-A signaling
was not long enough to cause other phenotypic changes. It is
TABLE 1 also possible that the embryo requires only that either PDGF-
A or PDGF-B be present, not both.Phenotypic Abnormalities Observed in Anti-PDGF-A-
Injected Embryos The ®ndings here demonstrate for the ®rst time that
PDGF-A is required for normal embryonic development.
Defect Age Affected P a Disruption of PDGF-A ligand±receptor interactions results
in a different but overlapping array of embryonic abnormali-Resorption E8.5 8% 0.31
ties, depending on the embryonic age at which the disrup-E9.5 18% 0.85
tion occurs. By injecting antibodies in utero we have beenE10.5 14% 0.26
Aortic in¯ation E8.5 { able to obtain information about the temporal requirements
E9.5 { of the embryo for PDGF-A that could not have been ascer-
E10.5 48% .001 tained from the analysis of knockout mice. We believe that
Thickened heart wall E8.5 29% 0.02 this is a powerful technique that can be applied to many
E9.5 17% 0.08 systems to screen for developmental abnormalities, perhaps
E10.5 16% 0.007
as a precursor to doing costly time consuming knockouts.Subpericardial blood E8.5 {
Further, it can complement knockout mice by helping toE9.5 {
de®ne critical developmental periods and processes that re-E10.5 38% .001
quire the knocked out factor.Heart wall perforations E8.5 Ð
E10.5 7% .14
Thoracic wall thinning E8.5 Ð
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